Drug Profile
Research programme: asthma therapeutics - Medigreen Biotechnology
Alternative Names: 1217BLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medigreen Biotechnology Corporation
- Class
- Mechanism of Action Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in China
- 01 Aug 2007 Preclinical trials in Asthma in China (unspecified route)